Conditional siRNA Sensor Design for Specific mRNA Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNAi therapies face challenges in developing targeted and conditionally activated approaches that can selectively restrict RNA interference to specific populations of disease-related cells, while minimizing off-target effects and improving drug potency, sensitivity, and stability.
Innovation Solution
A method for designing a nucleic acid strand involves generating a consensus sequence for mRNA variants of a gene, creating candidate sequence segments, and selecting complementary segments based on secondary structure energy and matching sequences to design a nucleic acid strand for specific binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional RNAi therapy is used, then RNA interference can be achieved, but off-target effects occur and specificity is reduced
Solution Approach 1:
The patent implements conditional activation of RNAi therapy through dynamic control mechanisms. The RNAi agent is designed to remain inactive until a specific cellular condition is met, at which point it becomes active. This dynamic approach allows the therapy to selectively target disease-related cells while sparing healthy cells, thereby improving specificity and reducing off-target effects.
Solution Approach 2:
The patent applies local quality by designing RNAi agents with conditionally activatable features that are specific to certain cell types or conditions. The activation mechanism is localized to particular cellular environments (e.g., presence of specific miRNAs, pH conditions, or enzymatic activities), ensuring that the RNAi effect is exerted only where needed, thus enhancing specificity and minimizing off-target effects.
2Reliability
If RNAi therapy is applied broadly, then more target cells can be treated, but drug potency and sensitivity are reduced
Solution Approach 1:
The conditional activation mechanism enables the RNAi agent to concentrate its effect on target cells that meet specific conditions. This dynamic control improves drug potency by ensuring that the active ingredient is only present and active where the disease is present, rather than being distributed broadly throughout the body. Consequently, lower dosages are required to achieve therapeutic effects.
3Reliability
If conditionally activatable RNAi is designed, then specificity and potency are improved, but design complexity increases
Solution Approach 1:
The patent employs intermediary elements such as conditional promoters, riboswitches, or aptamer sequences that mediate between the RNAi agent and the cellular condition. These intermediaries sense specific cellular conditions (e.g., presence of disease-related miRNAs, pH levels, or enzymatic activities) and trigger activation of the RNAi agent accordingly. This approach achieves conditional activation with improved specificity while managing design complexity through the use of well-characterized intermediary components.
4Stability of the object's composition
If traditional RNAi agents are used, then simplicity is maintained, but stability and sensitivity are reduced
Solution Approach 1:
The patent employs composite RNAi agent designs that combine multiple functional elements into a single therapeutic molecule. These composite structures may include conditionally activatable sequences, stabilization elements, and target-specific regions integrated into one construct. This composite approach enhances both stability (through protective elements and conditional activation that prevents premature degradation) and sensitivity (through optimized target recognition sequences), achieving improved performance while managing design complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The designed nucleic acid strand enables conditionally activated RNA interference with improved specificity and potency, reducing off-target effects and requiring lower dosages, thereby enhancing the therapeutic efficacy of RNAi therapies.
Implementation Method 1
selecting the complementary candidate segments having the lowest numbers of matching sequences and the highest secondary structure energies as the nucleic acid strand designed for specific binding of the mRNA variants of the gene
Data Source
AI summary
Provided herein include methods, systems, and compositions for designing a sensor nucleic acid strand of a conditionally activatable small interfering RNA (siRNA) complex as well as the siRNA complexes generated using the method herein described and the component strands. The siRNA complex can be conditionally activated upon a complementary binding to an input nucleic acid strand (e.g. a mRNA of a biomarker gene specific to a target cell) through a sequence in a sensor nucleic acid strand of the nucleic acid complex. The activated nucleic acid complex can release a potent RNAi duplex formed by a core nucleic acid strand and a passenger nucleic acid strand, which can specifically inhibit a target RNA.